Protein&Cell

Therapeutic Antibodies

May 2018
Volume 9
Issue 1
pp: 1-139

“Magic Bullets” at the center stage of immune therapy: a special issue on therapeutic antibodies

Zhiqiang An

2018, 9(1): 1-2 doi: 10.1007/s13238-017-0488-1
In vitro-engineered non-antibody protein therapeutics

Rudo Simeon, Zhilei Chen

2018, 9(1): 3-14 doi: 10.1007/s13238-017-0386-6
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins

Liming Liu

2018, 9(1): 15-32 doi: 10.1007/s13238-017-0408-4
Antibody-drug conjugates: recent advances in conjugation and linker chemistries

Kyoji Tsuchikama, Zhiqiang An

2018, 9(1): 33-46 doi: 10.1007/s13238-016-0323-0
Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy

Yusuke Mimura, Toshihiko Katoh, Radka Saldova, Roisin O'Flaherty, Tomonori Izumi, Yuka Mimura-Kimura, Toshiaki Utsunomiya, Yoichi Mizukami, Kenji Yamamoto, Tsuneo Matsumoto, Pauline M. Rudd

2018, 9(1): 47-62 doi: 10.1007/s13238-017-0433-3
IgG Fc engineering to modulate antibody effector functions

Xinhua Wang, Mary Mathieu, Randall J. Brezski

2018, 9(1): 63-73 doi: 10.1007/s13238-017-0473-8
Molecular and functional analysis of monoclonal antibodies in support of biologics development

Xin Wang, Zhiqiang An, Wenxin Luo, Ningshao Xia, Qinjian Zhao

2018, 9(1): 74-85 doi: 10.1007/s13238-017-0447-x
Current progress in innovative engineered antibodies

R. Strohl William

2018, 9(1): 86-120 doi: 10.1007/s13238-017-0457-8
Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig

Philip D. Bardwell, Matthew M. Staron, Junjian Liu, Qingfeng Tao, Susanne Scesney, Gail Bukofzer, Luis E. Rodriguez, Chee-Ho Choi, Jennifer Wang, Qing Chang, Feng Dong, Cherrie Donawho, Jieyi Wang, Christine M. Grinnell, Edit Tarcsa, Charles Hutchins, Tariq Ghayur, Jijie Gu

2018, 9(1): 121-129 doi: 10.1007/s13238-017-0429-z
A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys

Ciming Kang, Lin Xia, Yuanzhi Chen, Tianying Zhang, Yiwen Wang, Bing Zhou, Min You, Quan Yuan, Chi-Meng Tzeng, Zhiqiang An, Wenxin Luo, Ningshao Xia

2018, 9(1): 130-134 doi: 10.1007/s13238-017-0438-y

Previous: Metabolism and Disease
Next: Stem Cell and Aging

Current Issue

ISSN1674-800X
EISSN1674-8018
IF (2022) 21.1

Latest
Articles
Most
Download
Special
Issue

Correction to: Developing potent PROTACs tools for selective degradation of HDAC6 protein Zixuan An, Wenxing Lv, Shang Su, Wei Wu, Yu Rao doi: 10.1007/s13238-019-0613-4

Professor Li-Pin. King: a famous physiologist in China Wei Gong, Fangfang Wang, Yike Ying doi: 10.1007/s13238-018-0582-z

Retraction Note to: DDB1 and Cul4 are necessary for gene silencing and heterochromatin formation at pericentromeric regions in Neurospora Yingqiong Cao, Jicheng Wei, Silu Yang, Jinquan Sun, Hui Xu, Ying Wang, Yuanbiao Zhao, Qun He doi: 10.1007/s13238-014-0079-3

RETRACTED ARTICLE: DDB1 and Cul4 are necessary for gene silencing and heterochromatin formation at pericentromeric regions in Neurospora Yingqiong Cao, Jicheng Wei, Silu Yang, Jinquan Sun, Hui Xu, Ying Wang, Yuanbiao Zhao, Qun He doi: 10.1007/s13238-014-0067-7

View all >>

CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes Puping Liang, Yanwen Xu, Xiya Zhang, Chenhui Ding, Rui Huang, Zhen Zhang, Jie Lv, Xiaowei Xie, Yuxi Chen, Yujing Li, Ying Sun, Yaofu Bai, Zhou Songyang, Wenbin Ma, Canquan Zhou, Junjiu Huang doi: 10.1007/s13238-015-0153-5

Correction of β-thalassemia mutant by base editor in human embryos Puping Liang, Chenhui Ding, Hongwei Sun, Xiaowei Xie, Yanwen Xu, Xiya Zhang, Ying Sun, Yuanyan Xiong, Wenbin Ma, Yongxiang Liu, Yali Wang, Jianpei Fang, Dan Liu, Zhou Songyang, Canquan Zhou, Junjiu Huang doi: 10.1007/s13238-017-0475-6

Questions about NgAgo Shawn Burgess, Linzhao Cheng, Feng Gu, Junjiu Huang, Zhiwei Huang, Shuo Lin, Jinsong Li, Wei Li, Wei Qin, Yujie Sun, Zhou Songyang, Wensheng Wei, Qiang Wu, Haoyi Wang, Xiaoqun Wang, Jing-Wei Xiong, Jianzhong Xi, Hui Yang, Bin Zhou, Bo Zhang doi: 10.1007/s13238-016-0343-9

Current progress in innovative engineered antibodies R. Strohl William doi: 10.1007/s13238-017-0457-8

View all >>

Special issue for fighting COVID-19 January 2023 Volume 14 Issue 1 pp: 1-78

Microbiome—Towards Translation May 2021 Volume 12 Issue 5 pp: 315-435

DHODH inhibitors fight SARS-CoV-2 October 2020 Volume 11 Issue 10 pp: 699-782

View all >>

“Magic Bullets” at the center stage of immune therapy: a special issue on therapeutic antibodies

In vitro-engineered non-antibody protein therapeutics

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins

Antibody-drug conjugates: recent advances in conjugation and linker chemistries

Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy

IgG Fc engineering to modulate antibody effector functions

Molecular and functional analysis of monoclonal antibodies in support of biologics development

Current progress in innovative engineered antibodies

Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig

A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys

Correction to: Developing potent PROTACs tools for selective degradation of HDAC6 protein

Professor Li-Pin. King: a famous physiologist in China

Retraction Note to: DDB1 and Cul4 are necessary for gene silencing and heterochromatin formation at pericentromeric regions in Neurospora

RETRACTED ARTICLE: DDB1 and Cul4 are necessary for gene silencing and heterochromatin formation at pericentromeric regions in Neurospora

CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes

Correction of β-thalassemia mutant by base editor in human embryos

Questions about NgAgo

Current progress in innovative engineered antibodies

Special issue for fighting COVID-19

Microbiome—Towards Translation

DHODH inhibitors fight SARS-CoV-2

Advertising

Quick Links